[LCID Study Number: 2013-080]
S1207, Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everloimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy [LCID Study Number: 2013-080]
The primary objective of this study is to compare whether the addition of one year of everolimus, a chemortherapy typically used in kidney, pancreas, breast and brain cancer, to standard endocrine therapy improves invasive disease-free survival in patients with high-risk, hormone-receptor (HR) positive and HER2-negative breast cancer.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-9553